DataMeds AI, Inc. (MEDS) Stock: Corexa Pharmacy Eyes Stronger H2 2026 Growth

TLDR Corexa Pharmacy topped $600,000 in July revenue with a $7 million run rate. DataMeds expands GLP-1 access through oral and injectable treatment options. Health Lives Here is set for a September public rollout starting in North Carolina. Corexa adds supplements and non-GLP-1 medicines to broaden pharmacy sales reach. Former NFL players will support marketing [...]

The post DataMeds AI, Inc. (MEDS) Stock: Corexa Pharmacy Eyes Stronger H2 2026 Growth appeared first on Blockonomi.